Finance

Lists
CLDX:NASDAQ
Celldex Therapeutics Inc
$28.83
+1.05%
(+0.30) 1D
$28.83
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CLDX...
Open
$28.41
High
$30.01
Low
$28.00
Mkt. cap
2.26B
Avg. vol.
1.22M
Volume
544.31K
52-wk high
$45.14
52-wk low
$22.33
EPS
-$4.31
Beta
1.04
Shares outstanding
78.54M
No. of employees
198
Open
$28.41
High
$30.01
Low
$28.00
Mkt. cap
2.26B
Avg. vol.
1.22M
Volume
544.31K
52-wk high
$45.14
52-wk low
$22.33
EPS
-$4.31
Beta
1.04
Shares outstanding
78.54M
No. of employees
198
News stories
From web sources and news partners
About Celldex Therapeutics Inc
CEO-
Employees198
Founded1983
HeadquartersHampton, New Jersey, United States
SectorHealth Care
IndustryBiotechnology
Websitecelldex.com
Analyst ratings
Based on 11 analysts giving stock ratings to CLDX in the past 3 months
Strong buy
Buy
10
Hold
1
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for CLDX in the last 3 months.
Highest
Current $28.83
$100.00 (+246.86%)
Average
$67.18 (+133.02%)
Lowest
$29.00 (+0.59%)
Analyst
Recommendation
Action
Price target
Projected
Date
Judah Frommer
Morgan Stanley
Buy
Reiterated
$61.00
+111.6%
11/09/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$61.00
+111.6%
11/09/2026
Edward Nash
Canaccord Genuity
Buy
Reiterated
$68.00
+135.9%
11/09/2026
Richard Law CFA
Goldman Sachs
Hold
Maintained
$29.00
+0.6%
11/06/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$72.00
+149.7%
11/05/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Reiterated
$68.00
+135.9%
11/06/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$64.00
+122%
11/06/2026
Etzer Darout
Barclays
Buy
Maintained
$53.00
+83.8%
11/06/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$100.00
+246.9%
11/06/2026
Derek Archila
Wells Fargo
Buy
Maintained
$72.00
+149.7%
10/15/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$64.00
+122%
10/03/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
$88.00
+205.2%
09/23/2026
Unknown Analyst
Jefferies
Buy
Maintained
$68.00
+135.9%
08/07/2026
David Dai
UBS
Buy
Maintained
$45.00
+56.1%
06/16/2026
Andy Chen
Wolfe Research
Buy
Maintained
$44.00
+52.6%
06/14/2026
Yaron Werber
TD Cowen
Buy
Maintained
-
-
05/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
121.00K
15.00K
22.00K
-
Cost of goods sold
75.33M
73.00M
67.54M
67.41M
Cost of revenue
75.33M
73.00M
67.54M
67.41M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.94M
11.45M
13.10M
14.84M
Operating expense
11.94M
11.45M
13.10M
14.84M
Total operating expenses
87.27M
84.45M
80.64M
82.25M
Operating income
-87.15M
-84.44M
-80.62M
-82.25M
Other non operating income
-
-
-
-
EBT including unusual items
-81.32M
-78.68M
-73.50M
-75.56M
EBT excluding unusual items
-81.32M
-78.68M
-73.50M
-75.56M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-81.32M
-78.68M
-73.50M
-75.56M
Net profit margin
-67,204.13%
-524,566.67%
-334,104.55%
-
Earnings per share
-1.22
-1.18
-0.94
-0.96
Interest and investment income
5.84M
5.75M
7.12M
6.69M
Interest expense
-
-
-
-
Net interest expenses
5.84M
5.75M
7.12M
6.69M
Depreciation and amortization charges
-
-
-
-
EBITDA
-86.34M
-83.58M
-79.72M
-81.09M
Gain or loss from assets sale
-
3.00K
1.00K
47.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps